

ACTA MEDICINAE 4/2014 Gynekologie

Kompletní literatura

- 2 **Definice a historie robotiky v medicíně**
prof. MUDr. Radovan Pilka, Ph.D. Porodnicko-gynekologická klinika FN a LF UP Olomouc
- 2 **Aktuální trendy v antikoncepci**
MUDr. Jiří Zvolský Gynekologická ambulance, Opava
- 2 **Hyperaktivní močový měchýř: novinky v současné léčbě**
prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika, 1. LF UK a VFN, Praha
- 3 **Dvoudávkové očkovací schéma HPV vakcín**
MUDr. Borek Sehnal Onkogynekologické centrum, Gynekologicko-porodnická klinika, Nemocnice Na Bulovce a 1. LF UK, Praha
- 3 **Odporované postupy při léčbě bakteriální vaginózy**
MUDr. Zuzana Petrovičová Gynekologická ambulancia Familia Sana, s. r. o., Banská Bystrica, SR
- 3 **Novinky ve farmakologické léčbě vulvovaginální kandidózy**
doc. MUDr. Jiří Špaček, Ph.D., IFEPAG Porodnická a gynekologická klinika FN a LF v Hradci Králové
- 4 **Je riziko tromboembolické nemoci při užívání kombinované hormonální antikoncepce závažné?**
MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 4 **Je čas na nová doporučení k hormonální substituční terapii?**
MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 4 **Chronická žilní onemocnění pohledem gynekologa/porodníka**
MUDr. Adam Neumann Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha
- 5 **Farmakologická léčba karcinomu děložního hrdla**
MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno
- 5 **Karcinom ovaria – 2014**
MUDr. Zdeněk Adamík, Ph.D. | MUDr. Soňa Krupková
Univerzita Tomáše Bati Zlín, Krajská nemocnice T. Bati, a. s., gynekologicko-porodnické oddělení
- 5 **Současné možnosti a novinky v léčbě karcinomu prsu**
MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
- 6 **Použití sakrální neurostimulace v léčbě dysfunkcí dolních močových cest**
MUDr. Michal Rejchrt Urologická klinika UK 2. LF a FN Motol, Praha
- 6 **Imunoterapie onemocnění vyvolaných infekcí lidskými papilomaviry**
RNDr. Ruth Tachezy, Ph.D. | RNDr. Michal Šmahel, Ph.D.
Oddělení experimentální virologie, Ústav hematologie a krevní transfuze, Praha
- 7 **Mamografie očima praktického lékaře**
MUDr. Zuzana Miškovská, Ph.D. Společnost všeobecného lékařství ČLS JEP
- 7 **Rámcový pohled na DM a řízení motorových vozidel s ohledem na hypoglykemie a zákonné úpravy**
MUDr. Jan Brož | MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 2. LF UK a FN Motol, Praha
JUDr. Martin Valdauf Lesy, a. s.
MUDr. Jan Polák, Ph.D. Centrum pro výzkum diabetu, metabolismu a výživy 3. LF UK a FN KV, Praha
- 7 **Novinky v léčbě bolesti v ordinaci praktického lékaře**
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti, ARK, LF MU a FN u sv. Anny v Brně
- 7 **Imunosupresiva – minulost, současnost a budoucnost**
MUDr. Marta Sobotková Ústav imunologie 2. LF a FN v Motole, Praha

Definice a historie robotiky v medicíně

prof. MUDr. Radovan Pilka, Ph.D. Porodnicko-gynekologická klinika FN a LF UP Olomouc

- 1 Yates, D. R. – Vaessen, C. – Rouprêt, M.: From Leonardo to da Vinci: the history of robot-assisted surgery in urology. *BJU International*, 2011, 108, s. 1708–1713.
- 2 Asimov, I.: *Runaround*, 1942.
- 3 Gourin, C. G. – Terris, D. J.: History of robotic surgery. *Nova Science*, New York, 2006.
- 4 Robot. In: *Dictionary M-WO* (ed.), 2012, dostupné z: <http://www.merriam-webster.com/dictionary/robot>, vyhledáno 14. 12. 2013.
- 5 <http://www.Robothallove.Org/unimate.html>, vyhledáno 14. 12. 2013.
- 6 Kwoh, Y. S. – Hou, J. – Jonckheere, E. A. – Hayati, S.: A robot with improved absolute positioning accuracy for ct guided stereotactic brain surgery. *IEEE transactions on bio-medical engineering*, 1988, 35, s. 153–160.
- 7 Bargar, W. L.: Robots in orthopaedic surgery: Past, present, and future. *Clinical orthopaedics and related research*, 2007, 463, s. 31–36.
- 8 Nishihara, S. – Sugano, N. – Nishii, T. – Tanaka, H. – Nakamura, N. – Yoshikawa, H. – Ochi, T.: Clinical accuracy evaluation of femoral canal preparation using the robodoc system. *Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association*, 2004, 9, s. 452–461.
- 9 Zipper, S. G. – Puschmann, H.: Nerve injuries after computer-assisted hip replacement: Case series with 29 patients. *Zeitschrift für Orthopädie und ihre Grenzgebiete*, 2005, 143, s. 399–402.
- 10 Cobb, J. – Henckel, J. – Gomes, P. – Harris, S. – Jakopec, M. – Rodriguez, F. – Barrett, A. – Davies, B.: Hands-on robotic unicompartmental knee replacement: A prospective, randomised controlled study of the acrobot system. *The Journal of bone and joint surgery British volume*, 2006, 88, s. 188–197.
- 11 Advincula, A. P. – Wang, K.: Evolving role and current state of robotics in minimally invasive gynecologic surgery. *Journal of minimally invasive gynecology*, 2009, 16, s. 291–301.
- 12 Pugin, F. B. P. – Morel, P.: History of surgery: from AESOP and ZEUS to da Vinci. *J Visc Surg*, 2011, 148, s. e3.
- 13 Satava, R. M.: Surgical robotics: The early chronicles: A personal historical perspective. *Surgical laparoscopy, endoscopy & percutaneous techniques*, 2002, 12, s. 6–16.
- 14 Mettler, L. – Ibrahim, M. – Jonat, W.: One year of experience working with the aid of a robotic assistant (the voice-controlled optic holder aesop) in gynaecological endoscopic surgery. *Human reproduction*, 1998, 13, s. 2748–2750.
- 15 Anvari, M. – McKinley, C. – Stein, H.: Establishment of the world's first telerobotic remote surgical service: For provision of advanced laparoscopic surgery in a rural community. *Annals of surgery*, 2005, 241, s. 460–464.
- 16 Falcone, T. – Goldberg, J. M. – Margossian, H. – Stevens, L.: Robotic-assisted laparoscopic microsurgical tubal anastomosis: A human pilot study. *Fertility and sterility*, 2000, 73, s. 1040–1042.
- 17 Intuitive Surgical I: History: The da vinci system. Dostupné z: <http://www.intuitivesurgical.com/company/history/system.html>, vyhledáno v roce 2012.
- 18 Antoniou, S. A. – Antoniou, G. A. – Koch, O. O. – Pointner, R. – Granderath, F. A.: Robot-assisted laparoscopic surgery of the colon and rectum. *Surgical endoscopy*, 2012, 26, s. 1–11.
- 19 Maeso, S. – Reza, M. – Mayol, J. A. – Blasco, J. A. – Guerra, M. – Andradas, E. – Plana, M. N.: Efficacy of the Da Vinci Surgical System in abdominal surgery compared with that of laparoscopy: a systematic review and meta-analysis. *Annals of surgery*, 2010, 252, s. 254–262.
- 20 Maan, Z. N. – Gibbins, N. – Al-Jabri, T. – D'Souza, A. R.: The use of robotics in otolaryngology-head and neck surgery: A systematic review. *American journal of otolaryngology*, 2012, 33, s. 137–146.
- 21 Al-Mufarrej, F. – Margolis, M. – Tempesta, B. – Strother, E. – Najam, F. – Gharagozloo, F.: From Jacobaeus to the da Vinci: Thoracoscopic applications of the robot. *Surgical laparoscopy, endoscopy & percutaneous techniques*, 2010, 20, s. 1–9.
- 22 Aboumarzouk, O. M. – Stein, R. J. – Eyraud, R. – Haber, G. P. – Chlosta, P. L. – Somani, B. K. – Kaouk, J. H.: Robotic versus laparoscopic partial nephrectomy: A systematic review and meta-analysis. *European urology*, 2012, 62, s. 1023–1033.
- 23 Montorsi, F. – Wilson, T. G. – Rosen, R. C. – Ahlering, T. E. – Artibani, W. – Carroll, P. R. – Costello, A. – Eastham, J. A. – Ficarra, V. – Guazzoni, G. – Menon, M., et al.: Best practices in robot-assisted radical prostatectomy: Recommendations of the pasadena consensus panel. *European urology*, 2012, 62, s. 368–381.
- 24 Pitter, M. C. – Anderson, P. – Blissett, A. – Pemberton, N.: Robotic-assisted gynaecological surgery-establishing training criteria; minimizing operative time and blood loss. The international journal of medical robotics + computer assisted surgery. *MRCAS*, 2008, 4, s. 114–120.
- 25 Intuitive Surgical I: *Investor faq*. Dostupné z: <http://investor.intuitivesurgical.com/phoenix.zhtml?c122359&pLirol-faq>, vyhledáno 23. 11. 2013.

Aktuální trendy v antikoncepci

MUDr. Jiří Zvolský Gynekologická ambulance, Opava

- 1 *JWT survey*: 2009/WZB, 2013/Modern Moms, 2009, UN, Department of Economic and Social Affairs, Population Division, World Data Bank, 2013/Advertising Age, 2009.
- 2 Hooper, D. J.: Attitudes, Awareness, Compliance and Preferences among Hormonal Contraception Users. A Global, Cross-Sectional, Self-Administered, Online Survey. *Clin Drug Invest*, 2010, 30 (11), s. 749–763.
- 3 Mansour, D.: International survey to assess women's attitudes regarding choice of daily versus nondaily female hormonal contraception. *International Journal of Women's Health*, 2014, 6, s. 367–375.
- 4 Trussell, J.: Contraceptive failure in the United States. *Contraception*, 2011, 83, s. 397–404.
- 5 Singh, S., et al.: Unintended pregnancy: Worldwide levels, trends, and outcomes. *Stud Fam Plann*, 2010, 41, s. 241–250.
- 6 Průzkum agentury IPSOS pro společnost Bayer v ČR, leden–únor 2014.
- 7 ÚZIS 2012 (Ústav zdravotnických informací a statistiky ČR).

Hyperaktivní močový měchýř: novinky v současné léčbě

prof. MUDr. Alois Martan, DrSc. Gynekologicko-porodnická klinika, 1. LF UK a VFN, Praha

- 1 Abrams, P. – Blaivas, J. G. – Stanton, S. L., et al.: The standardisation of terminology of lower urinary tract function. *Scand J Urol Nephrol*, 1988, 114, s. 5–19.
- 2 Abrams, P. – Cardovo, L. – Fall, M., et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *NeuroUrology*, 2002, 21, s. 167–178.
- 3 Banner, J. S. – Nichol, M. B. – Rovner, E. S., et al.: Patient-reported reasons for discontinuing overactive bladder medication. *BJU International*, 2009, 105, s. 1276–1282.
- 4 Buser, N. – Ivic, S. – Kessler, T. M., et al.: Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analyses. *Eur Urol*, 2012, 62, s. 1040–1060.
- 5 Caremel, R. – Loutochin, O. – Corcos, J.: What do we know and not know about mirabegron, a novel β_3 agonist, in the treatment of overactive bladder? *Int Urogynaecol J*, 2013, doi: 10.1007/s00192-013-2161-4.
- 6 de Groat, W. C.: Integrative control of the lower urinary tract: preclinical perspective. *Br J Pharmacol*, 2006, 147, s. S25–40.
- 7 Chapple, Ch. R. – Kaplan, S. A. – Mitcheson, D., et al.: Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β_3 -adrenoceptor agonist, in overactive bladder. *Eur Urol*, 2013, 63, s. 296–305.
- 8 Khullar, V. – Amarenco, G. – Angulo, J. C., et al.: Efficacy and tolerability of mirabegron, a β_3 -adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian Phase 3 Trial. *Eur Urol*, 2013, 63, s. 283–295.
- 9 Martan, A. – Horčíčka, L. – Hanuš, T., et al.: Prevalence žen s hyperaktivním močovým měchýřem v České republice. *Čes Gynék*, 2011, 76, s. 144–150.
- 10 Milsom, I. – Abrams, P. – Cardovo, L., et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU Int*, 2001, 87, s. 760.
- 11 Irwin, D. E. – Milsom, I. – Hunskaar, S., et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries; results of EPIC study. *Eur Urol*, 2006, 50, s. 1306–1314.
- 12 Stewart, W. F. – Corey, R. – Herzog, A. R., et al.: Prevalence of overactive bladder in women: results from the NOBLE program. *Int Urogynaecol J*, 2001, 12, s. S66.
- 13 Tikkinen, K. A. O. – Auvinen, A.: Does the imprecise definition of overactive bladder serve commercial rather than patient interests? *Eur Urol*, 2012, 61, s. 746–748.
- 14 Tyagi, P. – Thomas, C. A. – Yoshimura, N., et al.: Investigations into the presence of functional Beta 1, Beta 2 and Beta 3-adrenoceptors in urothelium and detrusor of human bladder. *Int Braz J Urol*, 2009, 35, s. 76–83.
- 15 Igawa, Y. – Aizawa, N. – Hojna, Y., et al.: Beta 3-adrenoceptors agonists: possible role in the treatment of overactive bladder. *Korean J Urol*, 2010, 51, s. 811–818.

Dvoudávkové očkovací schéma HPV vakcín

MUDr. Borek Sehnal Onkogynekologické centrum, Gynekologicko-porodnická klinika,
Nemocnice Na Bulovce a 1. LF UK, Praha

- 1 **Trollfors, B.**: Human papillomavirus vaccines: an outsider's point of view. *Expert Rev Vaccines*, 2008, 7, s. 1131–1133.
- 2 **De Vuyst, H. – Clifford, G. M. – Nascimento, M. C., et al.**: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer*, 2009, 124, s. 1626–1636.
- 3 **Tjalma, W. A. – Fiander, A. – Reich, O., et al.**: Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. *Int J Cancer*, 2013, 132, s. 854–867.
- 4 **Dobson, S. R. – McNeil, S. – Dionne, M., et al.**: Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. *JAMA*, 2013, 309, s. 1793–1802.
- 5 **Romanowski, B. – Schwarz, T. F. – Ferguson, L. M., et al.**: Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. *Hum Vaccin Immunother*, 2014, 10, s. 1374–1386.
- 6 **Kreimer, A. R. – Rodriguez, A. C. – Hildesheim, A., et al.**: Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. *J Natl Cancer Inst*, 2011, 103, s. 1444–1451.
- 7 **Moher, D. – Hopewell, S. – Schulz, K. F., et al.**: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*, 2010, 340, s. C869, doi: 10.1136/bmj.c869.
- 8 **Putthanakit, T. – Schwarz, T. – Esposito, S., et al.**: Immune response to a 2-dose schedule of the HPV-16/18 AS04-adjuvanted vaccine in girls (9–14) versus 3 doses in women (15–25): a randomized trial. Abstrakt. Ústní prezentace. Eurogin, 2013, Florencie, Itálie.
- 9 **Romanowski, B. – Schwarz, T. – Ferguson, L., et al.**: Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Abstrakt, poster. Eurogin, 2013, Florencie, Itálie.
- 10 **Lazcano-Ponce, E. – Stanley, M. – Muñoz, N., et al.**: Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. *Vaccine*, 2014, 32, s. 725–732.

Odporúčané postupy pri liečbe bakteriálnej vaginózy

MUDr. Zuzana Petrovičová Gynekologická ambulancia Familia Sana, s. r. o., Banská Bystrica, SR

- 1 **Kliment, M.**: *Probiotiká a gynekologický zápal, Probiotiká ako súčasť imunitného systému človeka*, 2012, s. 101–129.
- 2 **Štefanovič, J.**: *Lexikón lekárskej bakteriológie*. 2008, vydala SLK nákladom sekcie klinickej mikrobiológie Slovenskej lekárskej komory, 41.
- 3 **Kostiuk, P.**: Význam probiotík pri poruchách pošvového prostredia. *Edukafarm, Medinews*, 2008, 2, s. 84–85.
- 4 **Cauci, S., et al.**: Interrelationship of interleukin – 8 with interleukin-1 beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. *Mol Human Reprod*, 2003, 9, s. 53–58.
- 5 **Heinemann, C., et al.**: Purification and characterisation of a surface – binding protein from *Lactobacillus fermentum* RC-14 that inhibits adhesion of *Enterococcus faecalis* 1131. *FEMS Microbiol Lett*, 190, 1, s. 177–180.
- 6 *Highlights from the Third International Symposium on Vaginitis/Vaginosis*. Madeira, Portugalsko, 1994.
- 7 **Biswas, M. K.**: Bacterial Vaginosis. *Clinical Obstetrics & Gynecology*, 1993, 36, s. 166–176.
- 8 **ACOG Practice Bulletin Number 72: Clinical Management Guidelines For Obstetricians and Gynecologists. Vaginitis.** *Obst Gyn*, 2006, 107, s. 1195–1206.
- 9 **BASHH: National Guideline for the Management of Bacterial Vaginosis.** Clinical Effectiveness Group, British Association for Sexual Health and HIV, 2006, www.bashh.org, vyhledáno 2. 7. 2008.
- 10 **Guaschino, S., et al.**: SOPHY Study Group, SOPHY project: an observational study of vaginal pH and lifestyle in women of different ages and in different physiopathological conditions, Part I. *Minerva Ginecol*, 2008, 60, s. 105–114.
- 11 **Hay, P. E., et al.**: Reassessment of BV causation. *Int J STD and AIDS*, 2008, 19, s. 646–647.
- 12 **APGO Educational Series in Women's health Issues. Diagnosis of vaginitis**, 1996.
- 13 **Schwebke, J.**: Gynecologic consequences of bacterial vaginosis. *Obstet Gynecol Clin N Am*, 2003, 30, s. 685–694.
- 14 **Allsworth, J. E., et al.**: Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. *Obstet Gynecol*, 2007, 109, s. 114–120.
- 15 **Brotman, R. M., et al.**: A longitudinal study of vaginal douching and bacterial vaginosis – a marginal structural modeling analysis. *Am J Epidemiol*, 2008a, 168, s. 188–196.
- 16 **Brotman, R. M., et al.**: The effect of vaginal douching seccation on bacterial vaginosis: a pilot study. *AJ Obstet Gynecol*, 2008b, 198, s. e1–7.
- 17 **Allworth, J. E., et al.**: Viral Sexually Transmitted Infections and Bacterial Vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. *Sex Transm Dis*, 2008, Epub před tiskem.
- 18 **Sobel, J. D.**: Bacterial vaginosis. *Annu Rev Med*, 2000, 51, s. 349–356.
- 19 **Gallo, M. F., et al.**: Risk factors for incident herpes simplex type 2 virus infection among women attending a sexually transmitted disease. *Sex Transm Dis*, 2008, 35, s. 679–685.
- 20 **Kaul, R., et al.**: Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiplexsexually transmitted infections. *J Infect Dis*, 2007, 196, s. 1692–1697.
- 21 **Schwebke, J.**: Abnormal vaginal flora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases. *JID*, 2005, 192, s. 1315–1317.
- 22 **Koumans, E. H., et al.**: Preventing adverse sequelae of bacterial vaginosis. A public health program and research agenda. *Sexually Transmitted Diseases*, 2001, 28, s. 292–297.
- 23 **Atashili, J., et al.**: Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. *AIDS*, 2008, 22, s. 1493–1501.
- 24 **Amsel, R., et al.**: Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic association. *Am J Med*, 1983, 74, s. 14–22.
- 25 **Platz-Christensen, J. J., et al.**: Bacterial vaginosis and cervical intraepithelial neoplasia. *Acta Obstet Gynecol Scand*, 1994, 73, s. 586–588.
- 26 **Harmanli, O., et al.**: Urinary tract infections in women with bacterial vaginosis. *Obstet Gynecol*, 2000, 95, s. 710–712.

Novinky ve farmakologické léčbě vulvovaginální kandidózy

doc. MUDr. Jiří Špaček, Ph.D., IFEPAG Porodnická a gynekologická klinika FN a LF v Hradci Králové

- 1 **Buchta, V. – Špaček, J. – Jílek, P.**: Antiinfekční a antimykotická léčba. In: Špaček, J. – Buchta, V. – Jílek, P., et al.: *Vulvovaginální dyskomfort a poruchy poševního prostředí*. Grada, 2013, s. 289–317.
- 2 **Buchta, V. – Slezák, R. – Špaček, J., et al.**: Současné možnosti léčby kožních a slizničních mykóz. *Klin Farmakol Farm*, 2008, 22, s. 72–75.
- 3 **Cross, E. W. – Park, S. – Perlin, D. S.**: Cross-Resistance of clinical isolates of *Candida albicans* and *Candida glabrata* to over-the-counter azoles used in the treatment of vaginitis. *Microb Drug Resist*, 2000, 6, s. 155–161.
- 4 **Doležal, M. – Buchta, V.**: Aktuální pohled na skupinu antimykotik. *Praktické lékárenství*, 2006, 1, s. 10–14.
- 5 **Donders, G. – Bellen, G. – Byttebier, G., et al.**: Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCIDI trial). *Am J Obstet Gynecol*, 2008, 199, s. 613, e1–9.
- 6 **Donders, G. G. – Bellen, G. – Mendling, W.**: Management of recurrent vulvovaginal candidiasis as a chronic illness. *Gynecol Obstet Incest*, 2010, 70, s. 306–321.
- 7 **Friese, K. – Neumann, G. – Siebert, J.**: Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidiasis. *Arch Gynecol Obstet*, 2003, 268, s. 194–197.
- 8 **Hammer, K. A. – Carson, C. F. – Riley, T. V.**: Antifungal effects of *Melaleuca alternifolia* (tea tree) oil and its components on *Candida albicans*, *Candida glabrata* and *Saccharomyces cerevisiae*. *J Antimicrob Chemother*, 2004, 53, s. 1081–1085.
- 9 **Haria, M. – Brusin, H. M.**: Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. *Druha*, 1995, 49, s. 103–120.
- 10 **Hettiarachchi, N. – Ashbee, H. R. – Wilson, J. D.**: Prevalence and management of non-albicans vaginal candidiasis. *Sex Transm Infect*, 2010, 86, s. 99–100.
- 11 **Horowitz, B. J.**: Topical flucytosine therapy for chronic recurrent *Candida tropicalis* infections. *J Reprod Med*, 1986, 31, s. 821–824.
- 12 **Iavazzo, C. – Gkegkes, I. D. – Zarkada, I. M., et al.**: Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. *J Womens Health (Larchmt)*, 2011, 20, s. 1245–1255.
- 13 **Jovanovic, R. – Congema, E. – Nguyen, H. T.**: Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis. *J Reprod Med*, 1991, 36, s. 593–597.
- 14 **Lauper, U.**: Genital candidosis. *Curr Probl Dermatol*, 1996, 24, s. 123–131.
- 15 **MacNeill, C. – Weisz, J. – Carey, J. C.**: Clinical resistance of recurrent *Candida albicans* vulvovaginitis to fluconazole in the presence and absence of in vitro resistance. *J Reprod Med*, 2003, 48, s. 63–68.
- 16 **Mathema, B. – Gross, E. – Dun, E., et al.**: Prevalence of vaginal colonization by drug-resistant *Candida* species in college-age women with previous exposure to over-the-counter azole antifungals. *Clin Inf Dis*, 2001, 33, s. E23–7.
- 17 **Milne, J. D. – Warnock, D. W.**: Effect of simultaneous oral and vaginal treatment on the rate of cure and relapse in vaginal candidosis. *Br J Vener Dis*, 1979, 55, s. 362–365.
- 18 **Molteni, B. – D'Antonio, A. – Bandini, P., et al.**: Efficacy and tolerability of a new chlorhexidine-based vaginal gel in vaginal infections. *Curr Med Res Opin*, 2004, 20, s. 849–853.
- 19 **Nwokolo, N. C. – Boag, F. C.**: Chronic vaginal candidiasis. Management in the postmenopausal patient. *Drugs Aging*, 2000, 16, s. 335–339.
- 20 **Nystatin Multicenter Study Group.** Therapy of candidal vaginitis: the effect of eliminating intestinal *Candida*. *Am J Obstet Gynecol*, 1986, 155, s. 651–655.
- 21 **Pappas, P. G. – Kauffman, C. A. – Andes, D., et al.**: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 2009, 48, s. 503–535.
- 22 **Phillips, A. J.**: Treatment of non-albicans *Candida* vaginitis with amphotericin B vaginal suppositories. *Am J Obstet Gynecol*, 2005, 192, s. 2009–2012.
- 23 **Ray, D. – Goswami, R. – Banerjee, U., et al.**: Prevalence of *Candida glabrata* and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. *Diabetes Care*, 2007, 30, s. 312–317.
- 24 **Richter, S. S. – Galask, R. P. – Messer, S. A., et al.**: Antifungal susceptibilities of *Candida* species causing vulvovaginitis and epidemiology

of recurrent cases. *J Clin Microbiol*, 2005, 42, s. 2155–2162.

- 25 Singh, S. – Sobel, J. D. – Bhargava, P., et al.: Vaginitis due to *Candida krusei*: epidemiology, clinical aspects, and therapy. *Clin Infect Dis*, 2002, 35, s. 1066–1070.
- 26 Sivasubramanian, G. – Sobel, J. D.: Refractory urinary tract and vulvovaginal infection caused by *Candida krusei*. *Int Urogynecol J Pelvic Floor Dysfunct*, 2009, 20, s. 1379–1381.
- 27 Sobel, J. D.: Management of recurrent vulvovaginal candidiasis: unresolved issues. *Curr Infect Dis Rep*, 2006, 8, s. 481–486.
- 28 Sobel, J. D. – Faro, S. – Force, R. W., et al.: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. *Am J Obstet Gynecol*, 1998, 178, s. 203–211.
- 29 Sobel, J. D. – Chaim, W. – Nagappan, V., et al.: Treatment of vaginitis caused by *Candida glabrata*: use of topical boric acid and flucytosine. *Am J Obstet Gynecol*, 2003, 189, s. 1297–1300.
- 30 Sobel, J. D. – Wiesenfeld, H. C. – Martens, M., et al.: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med*, 2004, 351, s. 876–883.
- 31 Subissi, A. – Monti, D. – Togni, G., et al.: Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. *Druha*, 2010, 70, s. 2133–2152.
- 32 Špaček, J. – Buchta, V.: Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. *Mycoses*, 2005, 48, s. 165–171.
- 33 Špaček, J. – Buchta, V. – Jilek, P., et al.: Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. *European Journal of Obstetrics Gynecology and Reproductive Biology*, 2007, 131, s. 198–202.
- 34 Špaček, J. – Buchta, V. – Jilek, P., et al.: *Vulvovaginální dyskomfort a poruchy poševního prostředí*. Grada, 2013.
- 35 Watson, C. – Calabretto, H.: Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. *Aust N Z J Obstet Gynaecol*, 2007, 47, s. 262–272.
- 36 White, D. J. – Habib, A. R. – Vanthuyne, A., et al.: Combined topical flucytosine and amphotericin B for refractory vaginal *Candida glabrata* infections. *Sex Transm Infect*, 2001, 77, s. 212–213.

Je riziko tromboembolické nemoci při užívání kombinované hormonální antikoncepce závažné?

MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Stageman, B. H. – de Bastos, M. – Rosendaal, F. R., et al.: Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. *BMJ*, 2013, 347, s. 15298, doi: 10.1136.
- 2 Jick, H. – Jick, S. S. – Gurewid, V., et al.: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptive with different progestagen components. *Lancet*, 1995, 346, s. 1589–1593.
- 3 Vasilakis-Scarmozza, C. – Jick, H.: Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. *Lancet*, 2001, 358, s. 1427–1429.
- 4 WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. *Lancet*, 1997, 349, s. 102–109.
- 5 Thorogood, M.: Stroke and steroid hormonal contraception. *Contraception*, 1998, 53, s. S19–S25.
- 6 Spinillo, A. – Gorini, G. – Piazzi, G., et al.: The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. *Contraception*, 1996, 54, s. 163–168.
- 7 Vessey, M. – Metcalfe, A. – Wells, C., et al.: Ovarian neoplasms, functional ovarian cysts and oral contraceptives. *BMJ*, 1987, 294, s. 1518–1520.
- 8 Rabe, T. – Kowald, A. – Ortman, J., et al.: Inhibition of skin 5 α -reductase by oral contraceptive progestin in vitro. *Gynecol Endocrinol*, 2000, 14, s. 223–230.
- 9 Fernandez, E. – la Vecchia, C. – Franceschi, S., et al.: Oral contraceptive use and risk of colorectal cancer. *Epidemiology*, 1998, 9, s. 295–300.
- 10 Gross, T. P. – Schlesselman, J. J.: The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. *Obstet Gynecol*, 1994, 83, s. 419–424.
- 11 Schlesselman, J. J.: Oral contraceptives and neoplasia of the uterine corpus. *Contraception*, 1991, 43, s. 557–579.

Je čas na nová doporučení k hormonální substituční terapii?

MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Fait, T. – Donát, J. – Jeniček, J., et al.: Doporučení pro hormonální substituční terapii v postmenopauze. *Čes Gynek*, 2010, 75, s. 109–110.
- 2 Birkhauser, M. H. – Panay, N. – Archer, D. F., et al.: Updated recommendations for hormone replacement therapy in the peri- and postmenopause. *Climacteric*, 2008, 11, s. 108–124.
- 3 Utian, W. H. – Archer, D. F. – Bachmann, G. A.: Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. *Menopause*, 2008, 15, s. 584–602.
- 4 Archer, D. F. – Baber, R. J. – Barlow, D., et al.: Updated IMS recommendations on postmenopausal hormone therapy and preventive strategie for midlife health. *Climacteric*, 2011, 14, s. 302–320.
- 5 Sannten, R. J. – Alfred, D. C. – Ardoin, S. P., et al.: Postmenopausal Hormone Therapy. An Endocrine Society Scientific Statement. *J Clin Endocrinol Metabol*, 2010, 95, dopl. 1, s. S1–S66.
- 6 Nelson, H. D. – Walker, M. – Zakher, B. – Mitchell, J.: Menopausal hormone therapy for the primary prevention of chronic medication: a systematic review to update the U.S. Preventive Services Task Force recommendations. *Ann Intern Med*, 2012, 157, s. 104–111.
- 7 Fait, T. – Vrablík, M.: Coronary heart disease and hormone replacement therapy—from primary and secondary prevention to the window of opportunity. *Neuro Endocrinol Lett*, 2012, 33, dopl. 2, s. 17–21.
- 8 Marjoribanks, J. – Farquhar, C. – Roberts, H. – Lethaby, A.: Long term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev*, 2012, 7, CD004143, doi: 10.1002/14651858.CD004143.pub4.
- 9 Manson, J. E.: The Kronos Early Estrogen Prevention Study. *Womens Health (Lond Engl)*, 2013, 9, s. 9–11, doi: 10.2217/whe.12.69.
- 10 Schierbeck, L. L. – Rejnmark, L. – Tofteng, C. L., et al.: Effect of HRT on cardiovascular events in recently postmenopausal women. *BMJ*, 2012, 345, s. e6409, doi: 10.1136/bmj.e6409.
- 11 Kenemans, P. – Speroff, L.: Tibolone: Clinical recommendations and practical guidelines. *Maturitas*, 2005, 51, s. 21–28.

Chronická žilní onemocnění pohledem gynekologa/porodníka

MUDr. Adam Neumann Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha

- 1 Pospišilová, A. – Švestková, S.: Chronické žilní onemocnění je závažnější, než si připouštíme. *Medicina pro praxi*, 2010, 1, s. 50–54.
- 2 Pospišilová, A.: Symptomy u chronického žilního onemocnění. *Bulletin sdružení praktických lékařů ČR*, 2013, 3, s. 54–58.
- 3 Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Chronická žilní onemocnění. Centrum doporučených postupů pro praktické lékaře, 2011.
- 4 Kaletová, D.: Farmakologická léčba chronické žilní nemoci. *Angiologie*, 2009, 3, s. 96–104.
- 5 Boisseau, M. R.: Pharmacological targets of drugs employed in chronic venous and lymphatic insufficiency. *Int Angiol*, 2002, 21, s. 33–39.
- 6 Reich, S. – Altmayer, P. – Stucker, M.: Systemische medikamentöse Therapie von chronischen Venenerkrankungen. *Hautarzt*, 2006, 57, s. 9–18.
- 7 Vlachovský, R.: Use of venoactive drugs in surgical management of chronic venous disease (CVD). *Kazuistiky v angiologii*, 2014, 1, s. 34–35.
- 8 Perrin, M. – Nicolaidis, A.: The Updated International Guidelines on 'The Management of Chronic Venous Disorders of the Lower Limbs' and the Place of Venotonic Drugs. *Int Angiol*, prezentováno na Union Internationale de Phlébologie Congress, 8–13. září 2013, Boston, USA, 2013, 32, s. 106–107.
- 9 The Essentials from the XVIIth World Meeting of the Union Internationale de Phlébologie, 7–14 September 2013, Boston, USA. *Phlebology*, 2013, 20, s. 138–144.

Farmakologická léčba karcinomu děložního hrdla

MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno

- 1 ÚZIS ČR, NOR ČR 2013: *Novotvary*, 2010.
- 2 Thigpen, J. T. – Vance, R. – Punekey, L., et al.: Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. *Semin Oncol*, 1995, 22, s. 16–24.
- 3 Pectasides, D. – Kamposioras, G. – Papaxoinis, G.: Chemotherapy for recurrent cervical cancer. *Canc Treatm Reviews*, 2008, 34, s. 603–613.
- 4 Moore, D. H. – Blessing, J. A. – McQuellon, R. P., et al.: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *J Clin Oncol*, 2004, 22, s. 3113–3119.
- 5 Fiorica, J. – Holloway, R. – Ndubisi, B., et al.: Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. *Gynecol Oncol*, 2002, 85, s. 89–94.
- 6 Long III, H. J. – Bundy, B. N. – Grendys Jr., E. C., et al.: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. *J Clin Oncol*, 2005, 23, s. 4629–4633.
- 7 Monk, B. J. – Sill, M. W. – McMeekin, D. S., et al.: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*, 2009, 27, s. 4649–4655.
- 8 Tewari, K. S., et al.: Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med*, 2014, 370, s. 734–743.

Karcinom ovaria – 2014

MUDr. Zdeněk Adamík, Ph.D. | MUDr. Soňa Krupková

Univerzita Tomáše Bati Zlín, Krajská nemocnice T. Bati, a. s., gynekologicko-porodnické oddělení

- 1 Cibula, D. – Petruželka, L.: *Onkogynekologie*. Grada publishing, 2009, s. 49–59, 508–531.
- 2 Calda, P. – Břešťák, M. – Fisherová, D.: Ultrazvuková diagnostika v těhotenství a gynekologii. *Aprofeza*, 2010, 2, s. 459–467.
- 3 Kurman, R. J. – le-Ming Shih, M. D.: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the paradigm. *Human Pathology*, 2012, 42, s. 918–931.
- 4 Fathalla, M. F.: Incessant ovulation—a factor in ovarian neoplasia? *Lancet*, 1971, 298, s. 163.
- 5 Cramer, D. W. – Welch, W. R.: Determinants of ovarian cancer risk. *Natl Cancer Inst*, 1983, 71, s. 717–721.
- 6 Vanderhyden, B. C. – Shaw, T. J. – Ethier, J. F.: Animal model of ovarian cancer. *Reprod Biol Endocrinol*, 2003, 1, s. 1–11.
- 7 Zikán, M. – Cibula, D. – Fischerová, D., et al.: *Guideline gynekologických zhoubných nádorů: standard komplexní léčby ovariálních epitelálních zhoubných nádorů*. www.onkogynekologie.com.
- 8 Shih, K. K. – Chi, D. S.: Maximal cytoreductive effort in epithelial ovarian cancer surgery. *J Gynecol Oncol*, 2010, 21, s. 75–80.
- 9 Kehoe, S. M. – Eisenhauer, E. L. – Chi, D. S.: Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy. *Gynecol Oncol*, 2008, 111, s. 51–55.
- 10 Klener, P., et al.: *Klinická onkogynekologie*. Galén, 2002, s. 485–487.

Současné možnosti a novinky v léčbě karcinomu prsu

MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

- 1 Ligibel, L.: Lifestyle factors in cancer survivorship. *J Clin Oncol*, 2012, 20–30, s. 3697–3704.
- 2 Visvanathan, K. – Hurley, P. – Bantug, E., et al.: Use of pharmacologic intervention for breast cancer risk reduction: ASCO clinical practice guideline. *J Clin Oncol*, 2012, 31, s. 2942–2962.
- 3 Hudis, C. A.: Trastuzumab—mechanism of action and use in clinical practice. *N Engl J Med*, 2007, 357, s. 39–51.
- 4 Cho, S. – Mason, K. – Raymar, K. X., et al.: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature*, 2003, 421, s. 756–760.
- 5 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 2001, 344, s. 783–792.
- 6 Pegram, M. D. – Polez, A. – Konečný, G., et al.: Trastuzumab and chemotherapeutics: drug interactions and synergies. *Semin Oncol*, 2000, 27, s. 21–25.
- 7 Vogel, C. L. – Cobleigh, M. A. – Tripathy, D., et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol*, 2002, 20, s. 719–726.
- 8 Burstein, H. J. – Harris, L. N. – Marco, P. K., et al.: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. *J Clin Oncol*, 2003, 21, s. 2889–2895.
- 9 Xu, L. – Song, S. – Zhu, J., et al.: Capecitabine (X) + trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): Phase II trial results. *Breast Cancer Res Treat*, 2006, 100, abstrakt 2065.
- 10 Seidman, A. D. – Berry, D. – Cirrioncione, C., et al.: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. *J Clin Oncol*, 2008, 26, s. 1642–1649.
- 11 Kaufman, B. – Mackey, J. R. – Clemens, M. R., et al.: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM Study. *J Clin Oncol*, 2009, 27, s. 5529–5537. Epub 28. 9. 2009.
- 12 von Minckwitz, G. – Schwedler, K. – Schmidt, M., et al.: Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. *Eur J Cancer*, 2011, 47, s. 2273–2281.
- 13 Romond, E. – Suman, V. J. – Jeong, J.-H., et al.: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. *San Antonio Breast Cancer Symposium*, 2012, abstrakt 55–5.
- 14 Slamon, D. J. – Eiermann, W. – Robert, N., et al.: Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*, 2011, 365, s. 1273–1283.
- 15 Spielmann, M. – Roche, H. – Humblet, Y., et al.: 3 year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. *Breast Cancer Res Treat*, 2007, 106, s. 572.
- 16 Perez, E. A. – Suman, V. J. – Davidson, N. E., et al.: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *J Clin Oncol*, 2011, 29, s. 4491–4497. Epub 31. 10. 2011.
- 17 Pivot, X. – Romieu, G. – Bonnefoi, H., et al.: PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. *San Antonio Breast Cancer Symposium*, 2012, abstrakt 55–3.
- 18 Dang, C. – Fornier, M. – Sugarman, S., et al.: The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. *J Clin Oncol*, 2008, 26, s. 1216–1222.
- 19 McArthur, H. L. – Mahoney, K. M. – Morris, P. G., et al.: Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. *Cancer*, 2011, 117, s. 5461–5468. Epub 16. 6. 2011.
- 20 Kiess, A. P. – McArthur, H. L. – Mahoney, K., et al.: Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. *Cancer*, 2012, 118, s. 1982–1988. Epub 1. 9. 2011.
- 21 Jones, S. – Collea, R. – Paul, D., et al.: Phase II trial of adjuvant TC (Docetaxel/Cyclophosphamide) plus trastuzumab (HER TC) in HER2-positive early stage breast cancer patients. *San Antonio Breast Cancer Symposium*: PD07-03, 2011.
- 22 Dang, C. T. – Tolaney, S. – Najita, J., et al.: Cardiac outcomes of patients on adjuvant weekly paclitaxel and trastuzumab for node negative, HER2 positive breast cancer. *San Antonio Breast Cancer Symposium*, 2011.
- 23 Gianni, L. – Eiermann, W. – Semiglazov, V., et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with parallel HER2-negative cohort. *Lancet*, 2010, 375, s. 377–384.
- 24 Buzdar, A. U. – Xia, R. – Burau, K., et al.: Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. *Med Oncol*, 2011, 28, s. 580–590. Epub 22. 10. 2010.
- 25 Chandralapaty, S. – Sakir, R. A. – Giri, D., et al.: Frequent mutational activation of the PI3K-AKT Pathway in trastuzumab-resistant breast cancer. *Clin Cancer Res*, 2012, 18, s. 6784–6791.
- 26 Konecny, G. E. – Pegram, M. D. – Venkatesan, N., et al.: Activity of dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab-treated breast cancer cells. *Cancer Res*, 2006, 66, s. 1630–1639.
- 27 Cameron, D. – Casey, M. – Olivia, C., et al.: Lapatinib plus capecitabine in women with HER2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial. *Oncologist*, 2010, 15, s. 924–934. Epub 24. 8. 2010.
- 28 Di Leo, A. – Gomez, H. L. – Aziz, Z., et al.: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. *J Clin Oncol*, 2008, 26, s. 5544–5552. Epub 27. 10. 2008.
- 29 Blackwell, K. L. – Burstein, H. J. – Storniolo, A. M., et al.: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. *J Clin Oncol*, 2012, 30, s. 2582–2592. Epub 11. 6. 2012.
- 30 Baselga, J. – Bradbury, I. – Eidtmann, H., et al.: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. *Lancet*, 2012, 379, s. 633–640. Epub 17. 1. 2012.
- 32 Guarneri, V. – Frassoldati, A. – Bottini, A., et al.: Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. *J Clin Oncol*, 2012, 30, s. 1989–1995. Epub 9. 4. 2012.
- 33 Untch, M. – Loibl, S. – Bischoff, J., et al.: Lapatinib versus trastuzumab

- in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 135–144. Epub 17. 12. 2012.
- 34 Juntilla, T. T. – Akita, W. – Parsons, K., et al.: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor. *Cancer Cell*, 2009, 15, s. 429–440.
- 35 Baselga, J. – Cortés, J. – Kim, S. B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366, s. 109–119. Epub 7. 12. 2011.
- 36 Gianni, L. – Pienkowski, T. – Im, Y.-H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neosphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32. Epub 6. 12. 2011.
- 37 Gail, D. – Lewis, P. – Guangmin, L., et al.: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer Res*, 2008, 68, s. 9280–9290.
- 38 Burris, H. A. 3rd. – Rugo, H. S. – Vukelja, S. J., et al.: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. *J Clin Oncol*, 2011, 29, s. 398–405. Epub 20. 12. 2010.
- 39 Dang, C. T. – Gianni, L. – Romieu, G., et al.: Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. *Am Soc Clin Oncol*, 2012, abstrakt 532.
- 40 Modi, S. – Stopeck, A. – Linden, H., et al.: HSP90 inhibition is effective in breast cancer: a phase II trial of tanesipimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. *Clin Cancer Res*, 2011, 17, s. 5132–5139. Epub 10. 5. 2011.
- 41 Awada, A. – Dirix, L. – Manso Sanchez, L., et al.: Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. *Ann Oncol*, 2013, 24, s. 109–116. Epub 11. 9. 2012.
- 42 Nagata, Y. – Lan, K. H. – Zhou, X., et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell*, 2004, 6, s. 117–127.
- 43 Saal, L. H. – Holm, K. – Maurer, M., et al.: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res*, 2005, 65, s. 2554–2559.
- 44 Kalinsky, K. – Jacks, L. M. – Heguy, A., et al.: PIK3CA mutation associates with improved outcome in breast cancer. *Clin Cancer Res*, 2009, 15, s. 5049–5059.
- 45 Reinholz, A. – Dueck, C. – Chen, B., et al.: Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. *Am Soc Clin Oncol*, 2011, abstrakt 10503.
- 46 Baselga, J. – Cortés, J. – Im, S.-A., et al.: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). *San Antonio Breast Cancer Symposium*, 2012, abstrakt S5–1.
- 47 Piccart-Gebhart, M. – Shinzaburo, M. – Pritchard, K., et al.: Everolimus for postmenopausal women with advanced breast cancer: Updates results of the BOLERO-2 phase III trial. *J Clin Oncol* (ASCO Annual Meeting Abstracts), 2012, 30, abstrakt 559.
- 48 Rocca, A. – Farolfi, A. – Bravaccini, S., et al.: Palbociclib (PD0332991): targeting the cell cycle machinery in breast cancer. *Expert Opin Pharmacotherapy*, 2014, 15, s. 407–420.
- 49 Cortes, J. – O'Shaughnessy, J. – Losech, D., et al.: Eribulin monotherapy versus treatment of physicians choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*, 2011, 377, s. 914–923.
- 50 Jacobs, C. – Simon, D. S. – Addison, C., et al.: Pharmacotherapy of bone metastases in breast cancer patients—an update. *Expert Opin Pharmacotherapy*, 2014, Epub před tiskem.
- 51 Kim, Y. – Je, Y.: Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. *Br J Cancer*, 2014.

Použití sakrální neurostimulace v léčbě dysfunkcí dolních močových cest

MUDr. Michal Rejchrt Urologická klinika UK 2. LF a FN Motol, Praha

- 1 Starkman, J. S. – Wolter, C. E. – Scarpero, H. M., et al.: Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation. *NeuroUrol Urodyn*, 2007, 26, s. 29–35.
- 2 van Kerrebroeck, P. E. – van Voskuilen, A. C. – Heesakkers, J. P., et al.: Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. *J Urol*, 2007, 178, s. 2029–2034.
- 3 Brazzelli, M. – Murray, A. – Fraser, C.: Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. *J Urol*, 2006, 175, s. 835–841.
- 4 Ruud Bosch, J. L. – Groen, J.: Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. *Lancet*, 1996, 348, s. 717–719.
- 5 Chartier-Kastler, E. J. – Ruud Bosch, J. L., et al.: Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. *J Urol*, 2000, 164, s. 1476–1480.
- 6 Kessler, T. M. – Framboise, D. – Trelle, S., et al.: Neuromodulation for neurogenic lower urinary tract dysfunction: Systematic review and meta-analysis. *Eur Urol*, 2000, 58, s. 53–62.

Imunoterapie onemocnění vyvolaných infekcí lidskými papilomaviry

RNDr. Ruth Tachezy, Ph.D. | RNDr. Michal Šmahel, Ph.D.

Oddělení experimentální virologie, Ústav hematologie a krevní transfuze, Praha

- 1 Walboomers, J. M. – Jacobs, M. V. – Manos, M. M. – Bosch, F. X. – Kummer, J. A. – Shah, K. V. – Snijders, P. J. – Peto, J. – Meijer, C. J. – Munoz, N.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol*, 1999, 189, s. 12–19.
- 2 zur Hausen, H.: Papillomavirus infections—a major cause of human cancers. *Biochim Biophys Acta*, 1996, 1288, s. F55–F78.
- 3 Gillison, M. L. – Alemany, L. – Snijders, P. J. – Chaturvedi, A. – Steinberg, B. M. – Schwartz, S. – Castellsague, X.: Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine*, 2012, 30, dopl. 5, s. F34–F54.
- 4 zur Hausen, H.: Papillomaviruses and cancer: from basic studies to clinical application. *Nat Rev Cancer*, 2002, 2, s. 342–350.
- 5 Munoz, N. – Castellsague, X. – de Gonzalez, A. B. – Gissmann, L.: Chapter 1: HPV in the etiology of human cancer. *Vaccine*, 2006, 24, dopl. 3, s. 1–10.
- 6 Vinokurova, S. – Wentzensen, N. – Kraus, I. – Klaes, R. – Driesch, C. – Melsheimer, P. – Kisseljov, F. – Durst, M. – Schneider, A. – von Knebel, D. M.: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. *Cancer Res*, 2008, 68, s. 307–313.
- 7 Rotnaglova, E. – Tachezy, R. – Salakova, M. – Prochazka, B. – Koslabova, E. – Vesela, E. – Ludvikova, V. – Hamsikova, E. – Klozar, J.: HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers. *Int J Cancer*, 2011, 129, s. 101–110.
- 8 Koutsky, L.: Epidemiology of genital human papillomavirus infection. *Am J Med*, 1997, 102, s. 3–8.
- 9 Sasagawa, T. – Takagi, H. – Makinoda, S.: Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. *J Infect Chemother*, 2012, 18, s. 807–815.
- 10 Schiller, J. T. – Castellsague, X. – Garland, S. M.: A review of clinical trials of human papillomavirus prophylactic vaccines. *Vaccine*, 2012, 30, dopl. 5, s. F123–F138.
- 11 Joura, E. A. – Garland, S. M. – Paavonen, J. – Ferris, D. G. – Perez, G. – Ault, K. A. – Huh, W. K. – Sings, H. L. – James, M. K. – Haupt, R. M.: Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. *BMJ*, 2012, 344, s. e1401.
- 12 Palefsky, J. M. – Giuliano, A. R. – Goldstone, S. – Moreira, E. D. Jr. – Aranda, C. – Jessen, H. – Hillman, R. – Ferris, D. – Coutlee, F. – Stoler, M. H. – Marshall, J. B. – Radley, D. – Vuocolo, S. – Haupt, R. M. – Garris, D. – Garner, E. I.: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*, 2011, 365, s. 1576–1585.
- 13 Kenter, G. G. – Welters, M. J. – Valentijn, A. R. – Lowik, M. J. – Berends-van der Meer, D. M. – Vloon, A. P. – Essahsah, F. – Fathens, L. M. – Offringa, R. – Drijfhout, J. W. – Wafelman, A. R. – Oostendorp, J. – Fleuren, G. J. – van der Burg, S. H. – Melief, C. J.: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *Br J Cancer*, 2010, 102, s. 1129–1136.
- 14 Daayana, S. – Elkord, E. – Winters, U. – Pawlita, M. – Roden, R. – Stern, P. L. – Kitchener, H. C.: Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. *Br J Cancer*, 2010, 102, s. 1129–1136.
- 15 Welters, M. J. – Kenter, G. G. – de Vos van Steenwijk, P. J. – Lowik, M. J. – Berends-van der Meer, D. M. – Essahsah, F. – Stynenbosch, L. F. – Vloon, A. P. – Ramwadhoebe, T. H. – Piersma, S. J. – van der Hulst, J. M. – Valentijn, A. R. – Fathens, L. M. – Drijfhout, J. W. – Franken, K. L. – Oostendorp, J. – Fleuren, G. J. – Melief, C. J. – van der Burg, S. H.: Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. *Proc Natl Acad Sci USA*, 2010, 107, s. 11895–11899.
- 16 Kenter, G. G. – Welters, M. J. – Valentijn, A. R. – Lowik, M. J. – Berends-van der Meer, D. M. – Vloon, A. P. – Drijfhout, J. W. – Wafelman, A. R. – Oostendorp, J. – Fleuren, G. J. – Offringa, R. – van der Burg, S. H. – Melief, C. J.: Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. *Clin Cancer Res*, 2008, 14, s. 169–177.
- 17 Welters, M. J. – Kenter, G. G. – Piersma, S. J. – Vloon, A. P. – Lowik, M. J. – Berends-van der Meer, D. M. – Drijfhout, J. W. – Valentijn, A. R. – Wafelman, A. R. – Oostendorp, J. – Fleuren, G. J. – Offringa, R. – Melief, C. J. – van der Burg, S. H.: Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. *Clin Cancer Res*, 2008, 14, s. 178–187.
- 18 van Poelgeest, M. I. – Welters, M. J. – van Esch, E. M. – Stynenbosch, L. F. – Kerpershoek, G. – van Persijn van Meerten, E. L. – van den Henden, M. – Lowik, M. J. – Berends-van der Meer, D. M. – Fathens, L. M. – Valentijn, A. R. – Oostendorp, J. – Fleuren, G. J. – Melief, C. J. – Kenter, G. G. – van der Burg, S. H.: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. *J Transl Med*, 2013, 11, s. 88.
- 19 Cao, Y. – Zhao, J. – Yang, Z. – Cai, Z. – Zhang, B. – Zhou, Y. – Shen, G. X. – Chen, X. – Li, S. – Huang, B.: CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. *Clin Immunol*, 2010, 136, s. 21–29.

- 20 Stern, P. L. – van der Burg, S. H. – Hampson, I. N. – Broker, T. R. – Flander, A. – Lacey, C. J. – Kitchener, H. C. – Einstein, M. H.: Therapy of human papillomavirus-related disease. *Vaccine*, 2010, 30, dopl. 5, s. F71–F82.
- 21 Stanley, M. A.: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. *Clin Exp Dermatol*, 2002, 27, s. 571–577.
- 22 Daayana, S. – Winters, U. – Stern, P. L. – Kitchener, H. C.: Clinical and immunological response to photodynamic therapy in the treatment of vulval intraepithelial neoplasia. *Photochem Photobiol Sci*, 2011, 10, s. 802–809.
- 23 Turksma, A. W. – Braakhuis, B. J. – Bloemena, E. – Meijer, C. J. – Leemans, C. R. – Hooijberg, E.: Immunotherapy for head and neck cancer patients: shifting the balance. *Immunotherapy*, 2013, 5, s. 49–61.
- 24 Pai, S. L.: Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. *Oncimmunology*, 2013, 2, s. e24065.

Mamografie očima praktického lékaře

MUDr. Zuzana Miškovská, Ph.D. Společnost všeobecného lékařství ČLS JEP

- 1 Harris, J. R. – Lippman, M. E. – Morrow, M. D. – Osborne, C. K.: *Diseases of the Breast*. Lippincott Williams – Wilkins, 2004, s. 1400.
- 2 Strnad, P. – Daneš, J.: *Nemoci prsu pro gynekology*. Grada, 2001.
- 3 Levret, S. r. o.: *Karcinom prsu. Moderní gynekologie a porodnictví*, 2004, 13, 3.
- 4 Daneš, J. – Bartoňková, H. – Skovajsová, M.: *Oficiální výsledky Národního programu mamografického screeningu v roce 2010*.
- 5 Strnad, P. – Miškovská, Z. – Herber, O.: *Včasný záchyt a management onemocnění prsu*. SVL ČLS JEP, 2005.
- 6 Česká republika. Úmluva na ochranu lidských práv a důstojnosti lidské bytosti v souvislosti s aplikací biologie a medicíny: Úmluva o lidských právech a biomedicině. *Sbírka mezinárodních smluv*, zákon č. 96/2001 Sb. m. s. Dostupné také z <http://aplikace.mvcr.cz/archiv2008/sbirka/2001/sb044-01m.pdf>.
- 7 Česká republika. *Zákon o zdravotních službách č. 372/2011 Sb.* Dostupné také z <http://portal.gov.cz/zakon/372/2011>.

Rámcový pohled na DM a řízení motorových vozidel s ohledem na hypoglykemie a zákonné úpravy

MUDr. Jan Brož | MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 2. LF UK a FN Motol, Praha
JUDr. Martin Valdauf Lesy, a. s.

MUDr. Jan Polák, Ph.D. Centrum pro výzkum diabetu, metabolismu a výživy 3. LF UK a FN KV, Praha

- 1 Jerome, L. – Habinski, L. – Segal, A.: Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique. *Curr Psychiatry Rep*, 2006, 8, s. 416–426.
- 2 Tregear, S. – Reston, J. – Schoelles, K. – Phillips, B.: Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. *J Clin Sleep Med*, 2009, 5, s. 573–581.
- 3 Lave, L. B. – Songer, T. J. – LaPorte, R. E.: Should persons with diabetes be licensed to drive trucks? Risk management. *Risk Anal*, 1993, 13, s. 327–334.
- 4 Kohrman, D. B.: Driving with diabetes: precaution, not prohibition, is the proper approach. *J Diabetes Sci Technol*, 2013, 7, s. 350–355.
- 5 MacLeod, K. M. – Hepburn, D. A. – Frier, B. M.: Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. *Diabet Med*, 1993, 10, s. 238–245.
- 6 Leese, G. P. – Wang, J. – Broomhall, J.: Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2. *Diabetes Care*, 2003, 26, s. 1176–1180.
- 7 Pedersen-Bjergaard, U. – Pramming, S. – Heller, S. R., et al.: Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. *Diabetes Metab Res Rev*, 2004, 20, s. 479–486.
- 8 Brož, J. – Donicová, V. – Brabec, M., et al.: Could continuous glucose monitoring facilitate identifying diabetes patients with a higher risk of hypoglycemia during driving? *J Diabetes Sci Technol*, 2013, 7, s. 1644–1645.
- 9 Cox, D. J. – Gonder-Frederick, L. A. – Kovatchev, B. P., et al.: Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. *Diabetes Care*, 2000, 23, s. 163–170.
- 10 Zákon č. 361/2000 Sb., o provozu na pozemních komunikacích. Dostupné z: <http://www.zakony.cz/seznamy/361-2000-Sb-zakon-o-provozu-na-pozemnich-komunikacich-a-o-zmenach-nekterych-zakonu.html>, vyhledáno 5. 2. 2014.
- 11 Vyhláška č. 72/2011 Sb. Dostupné z: <http://www.mdcrcz/NR/rdonlyres/214233D2-A72F-40C1-AB6A-CFA6EB4096B0/0/722011Sb.pdf>, vyhledáno 5. 2. 2014.

Novinky v léčbě bolesti v ordinaci praktického lékaře

MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti, ARK, LF MU a FN u sv. Anny v Brně

- 1 Bednařík, J. – Amber, Z. – Opavský, J. – Keller, O. – Rokyta, R. – Mazanec, R. – Lejčko, J. – Kozák, J. – Suchý, M. – Pátá, M. – Kožený, P.: *Klinický standard pro farmakoterapii neuropatické bolesti*. *Cesk Slov Neurol*, 2012, 75/108, s. 93–101.
- 2 Doležal, T.: *Lornoxicam v léčbě akutní a chronické bolesti*. *Farmakoterapie*, 2011, 7, s. 435–437.
- 3 Baron, R., et al.: 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. *Curr Med Res Opin*, 2009, 25, s. 1663–1676.
- 4 SPC léku Quenza.
- 5 Kabelka, L. – Kozák, J. – Lejčko, J. – Sláma, O.: Doporučený postup pro léčbu průlomové bolesti. *Bolest*, 2011, 14, dopl. 1.

Imunosupresiva – minulost, současnost a budoucnost

MUDr. Marta Sobotková Ústav imunologie 2. LF a FN v Motole, Praha

- 1 Hynie, S.: *Speciální farmakologie, díl VII/A Protinádorová chemoterapeutika a imunomodulační látky*. Karolinum, Praha, 2003, s. 104–123.
- 2 Carette, S.: All patients with rheumatoid arthritis should receive corticosteroids as part of their management. *J Rheumatol*, 2007, 34, s. 656–660.
- 3 Wall, R. L. – Conrad, F. G.: Cyclophosphamide therapy its use in leukemia, lymphoma and solid tumors. *Arch Intern Med*, 1961, 108, s. 456–482.
- 4 Prescilla, R. P.: *Immunosuppression*. Dostupné z: <http://emedicine.medscape.com>, vyhledáno 23. 7. 2013.
- 5 Maltzman, J. S. – Koretzky, G. A.: Azathioprine: old drug, new actions. *J Clin Invest*, 2003, 111, s. 1122–1124.
- 6 Bertino, J. R.: *Methotrexate: historical aspects*. In: Cronstein, B. N. – Bertino, J. R.: *Methotrexate*. Birkhäuser, Basel, 2000, s. 1–5.
- 7 Heusler, K. – Pletscher, A.: The controversial early history of cyclosporin. *Swiss Med Wkly*, 2001, 131, s. 299–302.
- 8 Bartůňková, J. – Sobotková, M.: Antibiotická imunosupresiva. *Remedia*, 2008, 3, s. 233–241.
- 9 Imbach, P.: Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. *Swiss Med Wkly*, 2012, 142, s. w13593.
- 10 Gaber, A. O. – Monaco, A. P. – Russell, J. A. – Lebranchu, Y. – Mohanty, M.: Rabbit antithymocyte globulin (thymoglobulin) 25 years and new frontiers in solid organ transplantation and haematology. *Drugs*, 2010, 70, s. 691–732.
- 11 <http://en.wikipedia.org>.
- 12 Bartůňková, J. – Sobotková, M.: Monoklonální protilátky a další biologická léčiva užívaná v imunosupresivní léčbě. *Remedia*, 2008, 4, s. 356–364.
- 13 Databáze léků dostupná z www.sukl.cz.